Common Oncology CPT Codes 2026 Chemotherapy Infusion Radiation and CAR T 

Last Updated on September 23, 2026

Oncology billing rarely depends on a single CPT code. One treatment episode may include an office visit, chemotherapy administration, separately billed drugs, supportive infusions, pathology testing, molecular diagnostics, and radiation services, each with its own coding and documentation requirements.

That complexity continues to grow with newer therapies and changing reporting rules. The American Cancer Society projects approximately 2,114,850 new cancer diagnoses in the United States in 2026, about 5,800 each day. 

For billing teams, the challenge is making sure every part of the treatment record reaches the claim accurately without duplicating services, losing administration time, misreporting drug units, or separating services that are already bundled.

Oncology CPT Codes Across the Treatment Journey

Different phases of oncology care generate different coding requirements.

The codes tell only part of the story. The treatment record must also establish why the service was performed, when it occurred, how it was delivered, and what was administered.

Billing Oncology E M Visits on Treatment Days 

Cancer treatment frequently involves office visits on the same day as chemotherapy or another drug administration service.

New-patient office visits generally fall within 99202–99205, while established-patient visits use 99211–99215, depending on applicable coding requirements.

There is an important Medicare distinction when treatment occurs on the same day.

CMS states that 99211 is included in chemotherapy and non-chemotherapy drug administration services and should not be separately reported. A higher-level office E/M service may be separately reportable with modifier 25 when the physician provides a significant, separately identifiable service beyond the drug administration.

The cancer diagnosis alone does not justify a higher E/M level. Documentation must support the medical decision-making or qualifying time used to select the visit code.

How Chemotherapy Administration Codes Build During an Encounter

Chemotherapy administration coding works as a hierarchy rather than a simple list of individual services. A typical IV chemotherapy encounter may progress like this:

• Initial chemotherapy infusion → 96413
• Additional qualifying infusion time → 96415
• A different chemotherapy drug infused sequentially → 96417
• Initial chemotherapy IV push → 96409
• Additional chemotherapy push of a different drug → 96411

CMS instructs providers to report actual infusion time. For time-based services, start and stop times or clearly supported total administration time are important for determining the appropriate code. CPT 96415 is used for qualifying additional chemotherapy infusion time after 96413, while 96417 describes an additional sequential infusion of a different chemotherapy substance. 

For a deeper explanation of one of the most frequently reported infusion codes, see our blog on CPT 96413 Chemotherapy Infusion Guide.

What the infusion record needs to show

• Drug or substance administered
• Route of administration
• Start and stop time
• Sequence of drugs
• Whether administration was infusion or push
• Additional infusion time
• IV access used
• Interruptions when clinically relevant

Drug Codes Units and JW JZ Reporting

The administration service and the drug itself are different billable components.

Think of the claim in two layers:

• CPT administration code – Describes how the drug entered the patient.
• HCPCS drug code – Identifies the drug or biological and the number of billable units.

For many oncology drugs, this means pairing an applicable chemotherapy administration CPT code with the appropriate HCPCS drug code and accurately converting the administered dose into billing units.

JW and JZ modifiers

For applicable separately payable Medicare Part B drugs supplied from single-dose containers or single-use packages: 

• JW identifies qualifying drug amounts that were unused and discarded.
• JZ indicates that no qualifying amount was discarded.

CMS requires the administered and discarded amounts to be reported correctly rather than billing the full container automatically.

A strong oncology charge review should therefore connect:

Ordered dose → prepared dose → administered dose → discarded amount → HCPCS units → JW or JZ

That chain is particularly important for high-cost infused therapies.

Supportive Infusion and Injection Coding

Not every medication delivered in an oncology infusion suite qualifies as chemotherapy administration.

Common supportive-care codes include:

• 96365 for the initial qualifying therapeutic, prophylactic, or diagnostic IV infusion
• 96366 for qualifying additional infusion time
• 96367 for an additional sequential infusion of a new therapeutic substance
• 96372 for applicable therapeutic, prophylactic, or diagnostic subcutaneous or intramuscular injections

Examples may include antiemetics, electrolyte replacement, antibiotics, hydration, and other supportive therapies depending on the substance and clinical situation.

CMS also notes that fluid used simply to administer a drug is incidental and should not automatically be reported as separate hydration. Concurrent and sequential services must be evaluated according to the applicable administration hierarchy. This is why simply counting every infusion bag can lead to incorrect coding.

Radiation Oncology Coding Changes for 2026

Radiation oncology experienced a meaningful coding change beginning January 1, 2026.

CMS explains that CPT 77402, 77407, and 77412 were revised into a technique-agnostic radiation treatment delivery family with applicable imaging incorporated into the delivery structure. As part of the change, CMS deleted radiation therapy HCPCS codes G6001–G6017 for the affected reporting workflow. 

CPT 77385 and 77386, previously used for IMRT delivery, were also deleted effective January 1, 2026. 

Billing teams should verify the applicable 2026 reporting requirements by site of service and payer rather than simply replacing every deleted code with the same new code. 

Radiation coding now requires teams to distinguish

• Planning – Examples include clinical treatment planning and dosimetry services.
• Treatment delivery – The applicable 2026 delivery code should reflect the service and current reporting rules.
• Treatment management – CPT 77427 remains relevant for qualifying radiation treatment management.
• Professional vs. technical responsibility – Component reporting should reflect who actually furnished the professional and technical portions when split billing applies.

For a broader look at coding, documentation, and component billing across oncology services, see our Oncology Coding and Billing Guidelines.

Pathology and Biomarker Testing in Oncology

Pathology coding sits at a critical point in the oncology journey because diagnosis, tumor classification, biomarkers, and treatment planning may all depend on laboratory findings.

Frequently encountered codes include:

The coding decision should follow the actual specimen and testing performed rather than the cancer diagnosis alone.

For more detail on specimen levels, immunohistochemistry, molecular testing, and pathology reporting, see our Pathology CPT Codes Guide.

Molecular Oncology CPT Codes

Molecular testing adds another layer because the code must represent the panel actually performed while the medical record supports why that testing was clinically appropriate.

Two frequently encountered examples are:

• 81445 for qualifying targeted genomic sequencing involving a smaller solid-tumor gene panel
• 81455 for qualifying larger solid-tumor genomic sequencing panels

Instead of treating these as automatic cancer-to-code combinations, review the full pathway:

Tumor diagnosis → test ordered → panel performed → coverage policy → medical necessity → treatment relevance when required

Payer coverage can vary considerably by tumor type, panel size, previous testing, and clinical indication. Prior authorization should therefore be verified when required rather than assumed based only on the CPT code. For testing and high-cost therapies that require payer approval, Prior Authorization Services can help coordinate clinical documentation, payer submission, and authorization follow-up. 

CAR T Coding From Collection to Administration

CAR T coding has changed significantly from older oncology references.

Effective January 1, 2025, CMS replaced the previous Category III CAR T procedure codes with four CPT codes representing distinct stages of the therapy lifecycle. 

Medicare billing note: Although 38225–38228 identify different CAR T procedural stages, CMS payment rules should also be reviewed because collection and preparation steps are not necessarily separately payable under OPPS or the Medicare Physician Fee Schedule. 

The coding sequence can therefore be understood as:

Harvest → Prepare for Transport → Receive and Prepare → Administer 

The CAR T product itself is reported through the applicable HCPCS product code where required. CMS currently lists product-specific Q-codes for several approved CAR T therapies, with applicable unclassified reporting available in certain circumstances for newer products. 

This is a good example of why oncology coding teams need to distinguish the therapy product from the clinical service used to collect, prepare, or administer it.

Diagnosis Coding Follows the Treatment Context

Oncology claims should not rely on fixed CPT-to-ICD-10 pairings.

Diagnosis selection may need to reflect:

• Active primary malignancy
• Metastatic disease
• Encounter for antineoplastic treatment where appropriate
• Treatment complications
• Adverse effects
• Symptoms or conditions being managed
• Personal history or status when clinically applicable

For example, Z51.11 may be relevant to an encounter for antineoplastic chemotherapy, but the complete diagnosis picture should reflect the patient’s documented clinical situation and payer requirements.

The key principle is:

The CPT code tells the payer what was done. The diagnosis coding must explain the clinical context supporting why it was done.

What Oncology Documentation Must Connect

A complete oncology claim may depend on information generated by several teams. Before billing, confirm that the record connects:

Treatment

• order and diagnosis
• drug and dose
• route
• timing and sequence

Billing

• HCPCS units
• wastage
• authorization

Specialty Documentation

1. radiation records
2. pathology/molecular results

When documentation gaps repeatedly affect code selection or charge capture, our guide to Common Oncology Billing Challenges explains where operational breakdowns commonly occur across complex treatment workflows.

The Oncology Claim Has Multiple Handoffs

Oncology billing accuracy depends on how well information moves across the treatment pathway.

A code can be technically correct and the claim can still be incomplete if one of these handoffs fails. Accurate oncology billing depends on coordination across physicians, infusion teams, pharmacy, pathology, radiation oncology, authorization, coding, and billing..

Oncology Billing That Connects Every Stage of Treatment

The complexity of oncology billing does not come from the number of CPT codes alone. It comes from the way multiple services, departments, and documentation sources converge on the same patient’s treatment pathway.

A chemotherapy encounter may require accurate infusion hierarchy, drug-unit conversion, JW/JZ reporting, and diagnosis alignment. Radiation services have their own planning, delivery, and management rules. Molecular diagnostics and CAR T therapy add payer-specific coverage and increasingly specialized coding requirements.

AnnexMed supports oncology practices and healthcare organizations across these interconnected workflows through oncology-specific coding, prior authorization, charge capture, claim submission, denial management, AR follow-up, and reimbursement review.

By connecting clinical documentation to the revenue cycle at each stage of treatment, AnnexMed helps oncology teams reduce gaps between the care delivered and the claim ultimately presented to the payer.

FAQs